Anosmia Rehabilitation in Patients Post Coronavirus Disease (COVID 19)

Sponsor
Lawson Health Research Institute (Other)
Overall Status
Withdrawn
CT.gov ID
NCT04374474
Collaborator
(none)
0
1
3
13.9
0

Study Details

Study Description

Brief Summary

The study will be a randomized controlled trial, involving patients with hyposmia/anosmia of onset immediately after an upper respiratory viral illness, assigned to three distinct study arms. Nasal irrigations will be prescribed to all three groups (BID). In addition, one arm will receive a paper hand-out about post-viral anosmia with instructions to smell common household items (current care) and act as a control group. The second group will receive an essential oil retraining kit, whereas the third group will receive the same olfactory training kit and a prescription to use budesonide with the nasal irrigations. Olfactory scores will be tested at the enrollment, 3 months and at 6 months.

Condition or Disease Intervention/Treatment Phase
  • Other: Olfactory retraining
  • Drug: corticosteroid nasal irrigation
  • Other: smell household Items
  • Other: Nasal Irrigation
Phase 4

Study Design

Study Type:
Interventional
Actual Enrollment :
0 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Olfactory Retraining Therapy and Budesonide Nasal Rinse for Anosmia Treatment in Patients Post-CoVID 19. A Randomized Controlled Trial
Anticipated Study Start Date :
Jan 10, 2021
Anticipated Primary Completion Date :
Dec 10, 2021
Anticipated Study Completion Date :
Mar 10, 2022

Arms and Interventions

Arm Intervention/Treatment
Sham Comparator: Control Group

The participants, randomly assigned to this arm, will receive a paper hand-out about post-viral anosmia with instructions to smell common household items (current care). Besides, it will be prescribed nasal irrigation twice a day.

Other: smell household Items
Participants will receive a paper hand-out about post-viral anosmia with instructions to smell common household items

Other: Nasal Irrigation
Participants from all three groups will use nasal rinse (NeilMed Sinus Rinse) two times a day.
Other Names:
  • Nasal Rinse
  • Experimental: Olfactory Retraining Group

    The participants, randomly assigned to this arm, will receive instructions on olfactory retraining and will also be given an essential oil retraining kit, which they will use twice a day. Besides, it will be prescribed nasal irrigation twice a day.

    Other: Olfactory retraining
    Olfactory retraining Olfactory training is performed by exposing patients twice daily to essential oils with four specific odors, present in glass jars with soaked cotton pads: phenyl ethyl alcohol, rose; eucalyptol, eucalyptus; citronellal, lemon; eugenol, cloves.
    Other Names:
  • essential oils kit
  • smell training
  • Other: Nasal Irrigation
    Participants from all three groups will use nasal rinse (NeilMed Sinus Rinse) two times a day.
    Other Names:
  • Nasal Rinse
  • Experimental: Olfactory Retraining_Budesonide Group

    The participants, randomly assigned to this arm, will receive instructions on olfactory retraining, the olfactory training kit and it will be prescribed nasal irrigation with Budesonise, twice a day.

    Other: Olfactory retraining
    Olfactory retraining Olfactory training is performed by exposing patients twice daily to essential oils with four specific odors, present in glass jars with soaked cotton pads: phenyl ethyl alcohol, rose; eucalyptol, eucalyptus; citronellal, lemon; eugenol, cloves.
    Other Names:
  • essential oils kit
  • smell training
  • Drug: corticosteroid nasal irrigation
    Nasal irrigation with corticosteroid (budesonide) consists of 240-mL nasal irrigation with Pulmicort Respules (0.5mg) across both nose sides via NeilMed Sinus Rinse bottle (Santa Rosa, California, USA).
    Other Names:
  • Budesonide nasal irrigation
  • Outcome Measures

    Primary Outcome Measures

    1. Change from Baseline Snap and Sniff Threshold Test at 3 months [3 months]

      Score from the Snap and Sniff Olfactory Test results

    2. Change from baseline Smell Identification Test (SIT) at 3 months [3 months]

      Score from the Smell Identification test results.

    3. Change from Baseline Snap and Sniff Threshold Test at 6 months [6 months]

      Score from the Snap and Sniff Olfactory Test results

    4. Change from baseline Smell Identification Test (SIT) at 6 months [6 months]

      Score from the Smell Identification test results.

    Secondary Outcome Measures

    1. Change from baseline QOD-NS at 3 months [3 months]

      Scores from the short version of the Questionnaire of Olfactory Disorders Negative Statements (QOD-NS)

    2. Change from baseline SF-36 health survey at 3 months [3 months]

      Short Form 36 Health Survey scores

    3. Change from baseline QOD-NS at 6 months [6 months]

      Scores from the short version of the Questionnaire of Olfactory Disorders Negative Statements (QOD-NS)

    4. Change from baseline SF-36 health survey at 6 months [6 months]

      Short Form 36 Health Survey scores

    5. Adherence to the Study Protocol [6 months]

      Adherence comparison between participants post-CoVID 19 and patients post other viral infections.

    6. Recovery [6 months]

      Compare the rate of recovery between post-COVID 19 patients and patients post other viral infections.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Adults 18 years of age or older

    • Hyposmia/anosmia of onset immediately after an upper respiratory viral illness confirmed on Snap n' Sniff threshold testing,

    • Capable, in the opinion of the primary investigator, of providing informed consent to participate in the study. Participants are required to sign an informed consent form indicating they understand the purpose and nature of the study, and that they are willing to participate.

    Exclusion Criteria:
    • active cigarette smoker

    • chronic rhinosinusitis

    • head trauma with loss of consciousness

    • inability to read/understand English

    • previous hyposmia/anosmia complaint

    • pregnancy

    • previous sinus

    • skull base or brain surgery

    • current participation in another clinical trial at the time of initial visit

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 St. Joseph's Health Care London Ontario Canada N5A 4V2

    Sponsors and Collaborators

    • Lawson Health Research Institute

    Investigators

    • Principal Investigator: Leigh Sowerby, MD, FRCSC, Western University

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    Responsible Party:
    Lawson Health Research Institute
    ClinicalTrials.gov Identifier:
    NCT04374474
    Other Study ID Numbers:
    • Anosmia_CoVID 19
    First Posted:
    May 5, 2020
    Last Update Posted:
    Feb 21, 2021
    Last Verified:
    Jul 1, 2020
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    No
    Keywords provided by Lawson Health Research Institute
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 21, 2021